The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome

  • Chunrong Li
  • Tianfei Luo
  • Yanwei Cheng
  • Shan Liu
  • Lifan Qiao
  • Xiujuan Wu
  • Kangding LiuEmail author
Original Article



Guillain-Barré syndrome (GBS) is a common acute immune-mediated inflammatory disorder affecting the peripheral nervous system (PNS) of humans. Studies in humans and in animal models revealed that neuropeptide Y (NPY) levels are altered in some neurodegenerative and neuroimmune disorders. Herein, we investigated the levels of NPY and cytokines in the serum of GBS patients and explored the roles of NPY in the disease severity and its short-term prognosis.


Twenty patients with GBS (case group) and twenty healthy individuals (control group) were enrolled in this study. NPY levels were analyzed by enzyme-linked immunosorbent assay (ELISA). The levels of pro- and anti-inflammatory cytokines (including interferon-γ (IFN-γ), interleukin (IL)-4, IL-10, IL-12p70, IL-17A, and tumor necrosis factor-α (TNF-α)) were analyzed using cytometric beads array (CBA). The clinical characteristics, disease severity, and short-term prognosis were compared between the two groups.


Compared with the control group, the levels of NPY and cytokines were significantly increased in the serum of patients with GBS. NPY levels in the serum of GBS patients were correlated with the disease severity.


Our results suggest that NPY and cytokines are involved in the pathogenesis of GBS. The levels of NPY can help to predict the severity of the disease.


Guillain-Barré syndrome Neuropeptide Y Cytokines Disease severity Short-term prognosis 



Guillain-Barré syndrome


Peripheral nervous system


Neuropeptide Y


Enzyme-linked immunosorbent assay






Tumor necrosis factor-α


Cytometric beads array


Central nervous system


Multiple sclerosis


Intravenous immunoglobulin


Hughes Functional Grading Scale


Medical Research Council


Statistical Product and Service Solutions


Experimental autoimmune neuritis




Helper T cell


Transforming growth factor β


Funding information

This study was supported by grants from The First Hospital, Jilin University Changchun, China General Program of the National Natural Science Foundation (No. 81771299).

Compliance with ethical standards

This study was approved by the ethics committee of the First Hospital of Jilin University, Changchun, China.

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10072_2019_4063_MOESM1_ESM.xls (30 kb)
ESM 1 (XLS 30 kb)


  1. 1.
    Wakerley BR, Yuki N (2013) Infectious and noninfectious triggers in Guillain-Barre syndrome. Expert Rev Clin Immunol 9(7):627–639CrossRefGoogle Scholar
  2. 2.
    Ziganshin RH, Ivanova OM, Lomakin YA, Belogurov AA Jr, Kovalchuk SI, Azarkin IV, Arapidi GP, Anikanov NA, Shender VO, Piradov MA, Suponeva NA, Vorobyeva AA, Gabibov AG, Ivanov VT, Govorun VM (2016) The pathogenesis of the demyelinating form of Guillain-Barre Syndrome (GBS): proteo-peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics 15(7):2366–2378CrossRefGoogle Scholar
  3. 3.
    Zhang HL, Zheng XY, Zhu J (2013) Th1/Th2/Th17/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev 24(5):443–453CrossRefGoogle Scholar
  4. 4.
    Ferreira R, Xapelli S, Santos T, Silva AP, Cristóvão A, Cortes L, Malva JO (2010) Neuropeptide Y modulation of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in microglia. J Biol Chem 285(53):41921–41934CrossRefGoogle Scholar
  5. 5.
    Maeda K, Yasuda M, Kaneda H, Maeda S, Yamadori A (1994) Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man. Neuropeptides. 27(6):323–332CrossRefGoogle Scholar
  6. 6.
    Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, Beck-Sickinger A, von Hörsten S, Yamamura T (2003) Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 171(7):3451–3458CrossRefGoogle Scholar
  7. 7.
    Levite M (1998) Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci U S A 95(21):12544–12549CrossRefGoogle Scholar
  8. 8.
    Hughes RA, Newsom-Davis JM, Perkin GD et al (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750–753CrossRefGoogle Scholar
  9. 9.
    Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14:1103–1109CrossRefGoogle Scholar
  10. 10.
    Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N (1996) Severe Guillain-Barre syndrome in childhood treated with human immune globulin. Pediatr Neurol 14(4):308–312CrossRefGoogle Scholar
  11. 11.
    Thorsell A, Mathe AA (2017) Neuropeptide Y in alcohol addiction and affective disorders. Front Endocrinol (Lausanne) 8:178CrossRefGoogle Scholar
  12. 12.
    Farzi A, Reichmann F, Holzer P (2015) The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol (Oxf) 213(3):603–627CrossRefGoogle Scholar
  13. 13.
    Kawamura N, Tamura H, Obana S, Wenner M, Ishikawa T, Nakata A, Yamamoto H (1998) Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 5(1–2):9–15CrossRefGoogle Scholar
  14. 14.
    Gonzalez-Rey E, Delgado-Maroto V, Souza Moreira L, Delgado M (2010) Neuropeptides as therapeutic approach to autoimmune diseases. Curr Pharm Des 16(28):3158–3172CrossRefGoogle Scholar
  15. 15.
    Puerto M, Guayerbas N, Alvarez P, De la Fuente M (2005) Modulation of neuropeptide Y and norepinephrine on several leucocyte functions in adult, old and very old mice. J Neuroimmunol 165(1–2):33–40CrossRefGoogle Scholar
  16. 16.
    Dimitrijević M, Stanojević S (2013) The intriguing mission of neuropeptide Y in the immune system. Amino Acids 45(1):41–53CrossRefGoogle Scholar
  17. 17.
    Singer K, Morris DL, Oatmen KE, Wang T, DelProposto J, Mergian T, Cho KW, Lumeng CN (2013) Neuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammation. PLoS One 8(3):e57929CrossRefGoogle Scholar
  18. 18.
    Painsipp E, Herzog H, Holzer P (2010) Evidence from knockout mice that neuropeptide-Y Y2 and Y4 receptor signalling prevents long-term depression-like behaviour caused by immune challenge. J Psychopharmacol 24(10):1551–1560CrossRefGoogle Scholar
  19. 19.
    Myhr K (2003) Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome. J Neuroimmunol 139(1–2):81–83CrossRefGoogle Scholar
  20. 20.
    Press ROV, Kouwenhoven M, Link H (2002) Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 58(3):476–478CrossRefGoogle Scholar
  21. 21.
    Hohnoki KIA, Koh CS (1998) Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. Neuroimmunol 87(1–2):27–32CrossRefGoogle Scholar
  22. 22.
    Nyati KKPK, Rizwan A, Verma A, Paliwal VK (2011) TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol 68(4):445–452CrossRefGoogle Scholar
  23. 23.
    Bao LLJ, van der Meide P, Sw Z, Ljunggren HG, Zhu J (2002) The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 12(4):420–429CrossRefGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  1. 1.Neuroscience Center, Department of NeurologyThe First Hospital of Jilin University, Jilin UniversityChangchunChina

Personalised recommendations